NDA's Approved Strategy Published

首页> 外文期刊>Nuclear future >NDA's Approved Strategy Published

【24h】

NDA's Approved Strategy Published

机译：NDA批准战略发布

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

At the end of March, the publication of the Nuclear Decommissioning Authority's approved Strategy, together with the approval for the sale of British Nuclear Group, placed a new emphasis on the worldwide importance of West Cumbria in the nuclear decommissioning and cleanup industry.

机译：3月底，核退役管理局批准的战略的发布，以及对出售英国核集团的批准，重新强调了西坎布里亚郡在核退役和清理行业的全球重要性。

著录项

来源
《Nuclear future》 |2006年第3期|p.108-109|共2页
作者

展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类原子能技术;
关键词

相似文献

外文文献
中文文献
专利

1. factor Xa inhibitor approved for use in this setting, exhibited similar short-term efficacy compared with enoxaparin, but reduced major bleeding and 30 day mortality. Therefore, in the context of early invasive or conservative strategy, fondaparinux was given a prominent place (class I recommendation) by both societies, notably in patients at risk of bleeding. Fondaparinux was preferred over enoxaparin (class IA vs. lla-B) in the ESC guidelines, regardless of initial strategy (excluding urgent r [J] . Health policy . 2009,第1期

机译：Xa因子Xa抑制剂被批准用于这种情况，与依诺肝素相比具有相似的短期疗效，但是减少了大出血和30天死亡率。因此，在早期侵入性或保守治疗策略的背景下，两个社会都将磺达肝癸钠列为突出位置（I类推荐），尤其是在有出血风险的患者中。在ESC指南中，无论初始策略如何（不包括紧急治疗），Fondaparinux均优于依诺肝素（IA级与Ila-B级）
2. Three standards published, two standards approved [J] . Nuclear news . 2014,第13期

机译：公布三项标准，批准两项标准
3. One standard approved, one published [J] . Nuclear news . 2011,第8期

机译：批准一项标准，一项已发布
4. ITRC: A State Regulator Strategy for Considering and Approving Technology Utilization Plans in Cleanup Projects [C] . Rick Tomlinson Exploring science-based solutions and technologies . 2002

机译：ITRC：一项考虑和批准清洁项目中技术使用计划的州监管策略
5. Exploring the Strategies Social Network Builders Need to Develop Information Privacy-Approved Social Networks [D] . Azzouz, Anas. 2019

机译：探索战略社交网络建设者需要开发信息隐私批准的社交网络
6. Alignment of Inhaled Chronic Obstructive Pulmonary Disease Therapies with Published Strategies. Analysis of the Global Initiative for Chronic Obstructive Lung Disease Recommendations in SPIROMICS [O] . Sohini Ghosh, Wayne H. Anderson, Nirupama Putcha, -1

机译：吸入性慢性阻塞性肺疾病治疗与已公布的策略的一致性。 SPIROMICS中的全球慢性阻塞性肺疾病建议倡议分析
7. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation31This document was approved by the American College of Cardiology Board of Trustees in August 2001, the American Heart Association Science Advisory and Coordinating Committee in August 2001, and the European Society of Cardiology Board and Committee for Practice Guidelines and Policy Conferences in August 2001.32When citing this document, the American College of Cardiology, the American Heart Association, and the European Society of Cardiology would appreciate the following citation format: Fuster V, Rydén LE, Asinger RW, Cannom DS, Crijns HJ, Frye RL, Halperin JL, Kay GN, Klein WW, Lévy S, McNamara RL, Prystowsky EN, Wann LS, Wyse DG. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation). J Am Coll Cardiol 2001;38:XX-XX.33This document is available on the World Wide Web sites of the American College of Cardiology (www.acc.org), the American Heart Association (www.americanheart.org), the European Society of Cardiology (www.escardio.org), and the North American Society of Pacing and Electrophysiology (www.naspe.org). Single reprints of this document (the complete Guidelines) to be published in the mid-October issue of the European Heart Journal are available by calling +44.207.424.4200 or +44.207.424.4389, faxing +44.207.424.4433, or writing Harcourt Publishers Ltd, European Heart Journal, ESC Guidelines – Reprints, 32 Jamestown Road, London, NW1 7BY, United Kingdom. Single reprints of the shorter version (Executive Summary and Summary of Recommendations) published in the October issue of the Journal of the American College of Cardiology and the October issue of Circulation, are available for $5.00 each by calling 800-253-4636 (US only) or by writing the Resource Center, American College of Cardiology, 9111 Old Georgetown Road, Bethesda, Maryland 20814. To purchase bulk reprints specify version and reprint number (Executive Summary 71-0208; full text 71-0209) up to 999 copies, call 800-611-6083 (US only) or fax 413-665-2671; 1000 or more copies, call 214-706-1466, fax 214-691-6342; or E-mail: pubauth@heart.org. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the North American Society of Pacing and Electrophysiology [O] . Fuster Valentin, Rydén Lars E., Asinger Richard W., 2001

机译：ACC / AHA / ESC治疗房颤患者指南31该文件于2001年8月获得美国心脏病学会董事会，2001年8月美国心脏协会科学咨询与协调委员会以及欧洲心脏病学会的批准以及实践指南和政策委员会会议（2001年8月）。32引用本文件时，美国心脏病学会，美国心脏协会和欧洲心脏病学会将赞赏以下引用格式：Fuster V，RydénLE，Asinger RW，Cannom DS，Crijns HJ，Frye RL，Halperin JL，Kay GN，Klein WW，LévyS，McNamara RL，Prystowsky EN，Wann LS，Wyse DG。 ACC / AHA / ESC治疗房颤患者的指南：美国心脏病学会/美国心脏协会实践指南工作组和欧洲心脏病学会实践指南委员会和政策会议的报告（制定指南委员会）用于房颤患者的治疗）。 J Am Coll Cardiol 2001; 38：XX-XX.33本文件可在美国心脏病学会（www.acc.org），美国心脏协会（www.americanheart.org），欧洲的万维网站点上找到心脏病学会（www.escardio.org）和北美起搏和电生理学会（www.naspe.org）。可致电+44.207.424.4200或+44.207.424.4389，传真+44.207.424.4433或写信给Harcourt Publishers，以获取本文档（完整的准则）的单份重印本（完整的准则），该印刷本将于10月中旬出版。欧洲心脏杂志，ESC指南–转载，英国伦敦詹姆斯敦路32号，NW1 7BY。短版（执行摘要和建议摘要）的单版重印在《美国心脏病学会杂志》十月刊和《循环》十月刊上，致电800-253-4636（仅美国），每本售价5.00美元。）或写信给美国心脏病学院资源中心，地址是：马里兰州贝塞斯达市Old Georgetown Road 9111，邮编20814。要购买批量转载，请指定版本和转载编号（执行摘要71-0208；全文71-0209），最多999份，致电800-611-6083（仅限美国）或传真413-665-2671； 1000或更多副本，请致电214-706-1466，传真214-691-6342;或电子邮件：pubauth@heart.org。美国心脏病学会/美国心脏协会实践指南工作组和欧洲心脏病学会实践指南和政策会议（制定房颤患者治疗指南委员会）的报告是与北方合作开发的美国起搏与电生理学会
8. Guidance for FDA Staff and Industry: Marketed Unapproved Drugs. Compliance Policy Guide. Sec. 440.100 Marketed New Drugs Without Approved NDAs or ANDAs (September 19, 2011) [R] . 2011

机译：FDa工作人员和行业指南：未经批准的未经批准的药物。合规政策指南。秒。 440.100未经批准的NDa或aNDa上市的新药（2011年9月19日）

NDA's Approved Strategy Published

摘要

著录项

相似文献

相关主题

期刊订阅